CervoMed reports Q1 2026 net loss of $8.0M; cash runway only into Sept 2026

CervoMed Inc.

Net loss $8.0M vs $4.9M YoY; no grant revenue vs $1.9M prior year.
Cash, cash equivalents and marketable securities $12.9M as of March 31, 2026, down from $20.9M at Dec 31, 2025.
Cash runway expected to fund operations into September 2026.
Plans to initiate Phase 3 DLB trial in H2 2026, subject to financing.
Presented new MRI and biomarker data at AAN 2026 and AD/PD 2026 supporting neflamapimod.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.